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Background: Pulmonary involvement is the main clinical and imaging feature 
of the novel corona virus disease (COVID-19). However, some patients present 
with upper airway symptoms.  
 
Aim: In this study, we report upper respiratory manifestations, specifically 
focusing on smell and taste disorders in COVID-19. 
 
Methods: We performed this cross-sectional prospective study in patients 
admitted to Masih Daneshvari Hospital, a tertiary referral center in Tehran, Iran, 
with severe COVID-19 as documented by the polymerase chain reaction assay. 
 
Results: We included 268 hospitalized patients, 183 (68.3%) men and 85 
(31.7%) women. The average age was 52.8±16.4. The sinonasal symptoms 
included nasal obstruction (44 [16.4%]), rhinorrhea (31 [11.5%]), sneeze (33 
[12.3%]), headache (77 [28.6%]), facial pain (12 [4.5%]), associated with 
hypogeusia (65 [24.2%]) and olfactory dysfunction (90 [33.5%]). In 35 (38.9%) 
patients with olfactory symptoms, change in the smell was the sole initial 
manifestation of COVID-19. On logistic regression, the relationship between 
the olfactory symptoms and headache (p=0.002), nasal obstruction (p=0.0001) 
and sneeze (p=0.018) were statistically significant. 
 
Conclusion: We report a considerable prevalence of olfactory and gustatory 
symptoms in hospitalized patients with COVID-19. Not infrequently, these 
symptoms were the sole initial presenting symptoms in the course COVID-19. 
During the current pandemic, we suggest that presence of these symptoms 
should mandate expedited screening for COVID-19, isolation and close 
monitoring of the patients for evolution of the clinical course.  
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Introduction 
In December 2019, several unexplained cases 
of pneumonia occurred in Wuhan, the capital of 
China’s Hubei province, later proven to have 
been caused by a novel coronavirus (CoV-2) 
(1). Severe acute respiratory distress (SARS) 
caused by CoV-2 infection in humans is similar 
to SARS-CoV and Middle East Respiratory 
Syndrome (MERS). The World Health 
Organization (WHO) has named the disease 
coronavirus disease 2019 (COVID-19) and has 
declared it a pandemic (2).  
SARS-CoV-2 is a betacoronavirus that is the 
seventh member of the Coronaviridae family of 
viruses (3). The whole-genome sequence of 
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SARS-CoV-2 has 96·2% similarity to a bat 
SARS-CoV and less similarity to the genomes 
of SARS-CoV or MERS-CoV (4,5). 
Nevertheless, SARS-CoV-2 uses the same 
receptor as the SARS-CoV, the angiotensin-
converting enzyme 2 (ACE2), for cell entry (4).  
COVID-19 is a recently reported disease that is 
increasingly recognised to involve different 
bodily organs. There is considerable data on the 
clinical and imaging findings of COVID-19 in 
the lower respiratory tract. However, 
information regarding manifestations in the 
upper respiratory tract is limited. While the 
most common symptoms at the onset of 
COVID-19 include fever, cough and fatigue, 
headache and upper respiratory symptoms are 
less common (6). Thus, more investigations on 
these manifestations and their potential causes 
in COVID-19 are warranted. In this study, we 
describe the upper respiratory tract and 
sinonasal manifestations, specifically the 
olfactory and gustatory symptoms, in patients 
hospitalized with confirmed SARS-CoV-2 
infection at a single referral center in Tehran, 
Iran; and describe the association between the 
upper respiratory symptoms and the olfactory 
and gustatory manifestations in this cohort of 
patients. 
Methods 
Patient population and study end points 
This cross-sectional study was performed at 
Masih Daneshvari Hospital in Tehran, Iran, 
which is a tertiary referral center for respiratory 
diseases. From March 1 to March 13, 2020, we 
prospectively collected data from consecutive 
adult (>18 years) hospitalized patients with 
confirmed SARS-CoV-2 infection by real-time 
polymerase chain reaction (PCR) performed on 
samples taken from pharyngeal swabs. The 
study population included patients who were 
hospitalized for COVID-19 and excluded the 
patients who were intubated and mechanically 
ventilated and the non-survivors. We asked the 
patients to fill in a questionnaire about the upper 
respiratory tract symptoms including nasal 
obstruction, rhinorrhea, sneeze, headache and 
facial pain. We divided the subjective olfactory 
complaints in three groups: anosmia for no 
sense of smell, hyposmia for reduced sense of 
smell, and parosmia for changed sense of smell, 
and defined the taste disorder as hypogeusia or 
reduced sense of taste. We recorded the time 
course of the olfactory and gustatory symptoms 
during the admission.  
Data were analysed using SPSS statistics 
version 22·0 (IBM, New York, NY, USA).  
Results 
Demographics and clinical characteristics of 
the study population  
The demographic and clinical characteristics of 
the study subjects are summarized in Table 1. A 
total of 268 hospitalized patients with 
confirmed SARS-CoV-2 infection were 
included in the study. The average age was 52.8 
± 16.4 years (range 20-93). 183 (68.3 %) were 
male and 85 (31.7 %) were female. The most 
common sinonasal symptoms were olfactory 
symptoms in 90 (33.5%), followed by headache 
in 77 (28.6 %) patients. Sinonasal symptoms 
were more prevalent in patients with olfactory 
or gustatory symptoms compared with patients 
who did not have these symptoms.  
Olfactory manifestations in patients with 
COVID-19 
The mean duration from the onset of illness to 
olfactory symptoms was 3.1±1.7 days. The 
mean age of patients was not different in 
patients with versus without olfactory 
symptoms (p> 0.05). We did not find a 
significant association between the olfactory 
symptoms and sex (p> 0.05). Moreover, 39 
(43.3%) patients had anosmia, 40 (44.5%) 
hyposmia, and 11(12.2%) parosmia. In 35 
(38.9%) of patients with olfactory symptoms, 
change in smell was the sole initial 
manifestation of COVID-19, whereas in 26 
(28.9%) of patients, olfactory symptoms and 
other symptoms of COVID-19 were 
simultaneously present. The onset of the 
olfactory symptoms was sudden in 37 (41.1%) 
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and gradual in 36 (40%) of patients, and 17 
(18.9%) patients did not recall the details of the 
symptom onset.  
There was associated headache in 20 (57.1%) 
patients in whom the first symptom of COVID-
19 was olfactory. Moreover, 17 (45.9%) 
patients with sudden onset of olfactory 
symptoms had headache. On logistic regression 
model, the relationship between the olfactory 
symptoms and headache (p=0.002), sneeze 
(p=0.018) and nasal obstruction (p=0.0001) 
were statistically significant (Table 2).  
 























Age 52·8 ± 16·4 50·6±15 53·86±17·05 47·8±14·6 54·35±16·67 0·147 0·007 
Sex  
Male 183 (68·3 %) 56 (62·2%) 126 (70·8%) 42 (64·6%) 141 (69·5%) 
0·183 0·600 
Female 85 (31·7%) 34 (37·8%) 52 (29·2%) 23 (35·4%) 62 (30·5%) 
Age decades  
20-30 22 (8·2%) 11 (12·2%) 13 (7·3%) 9 (13·8%) 14 (6·9%) 
0·050 0·057 
31-40 56 (20·9%) 15 (16·7%) 40 (22·5%) 15 (23·1%) 40 (19·7%) 
41-50 50 (18·7%) 20 (22·2%) 30 (16·8%) 13 (20%) 37 (18·2%) 
51-60 51 (19%) 19 (21·1%) 31 (17·4%) 15 (23·1%) 36 (17·8%) 
61-70 48 (17·9%) 18 (20%) 30 (16·8%) 9 (13·8%) 39 (19·2%) 




    Nasal 
obstruction 
44 (16·4%) 33 (36·6%) 11 (6·2%) 22 (33·8%) 22 (10·8%) <0·0001 <0·0001 
    Rhinorrhea 31 (11·5%) 18 (20%) 13 (7·3%) 13 (20%) 18 (8·9%) 0·002 0·014 
    Sneeze 33 (12·3%) 24 (26·6%) 9 (3·4%) 14 (21·5%) 19 (9·3%) <0·0001 0·009 
    Headache 77 (28·6%) 48 (53·3%) 29 (16·2%) 28 (43%) 49 (24·1%) <0·0001 0·003 
    Facial pain 12 (4·5%) 11 (12·2%) 1 (0·56%) 6 (9·2%) 6 (2·9%) <0·0001 0032 
 
Gustatory manifestations in patients with 
COVID-19 
Of the participants in the study, 65 patients 
(24.2%) had a change in taste, all with 
hypogeusia. The mean age of patients with 
gustatory symptoms was lower than patients 
without gustatory symptoms (p=0.007) (Table 
1). We did not find a significant association 
between the gustatory symptoms and sex (p> 
0.05). Moreover, 49 (75.3%) patients with 
hypogeusia had a concomitant olfactory 
symptom. Among the 49 patients with 
concomitant gustatory and olfactory symptoms, 
olfactory change was the initial symptom in 27 
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(55.1%), whereas gustatory symptom was the 
first symptom in 9 (18.4%) and both olfactory 
and gustatory symptoms occurred 
simultaneously in 13 (26.5%) patients.  
Headache was the most common symptom in 
patients with both olfactory and gustatory 
symptoms (54%). We found a significant 
association between the gustatory symptoms 
and nasal obstruction (p=0.003) (Table-2).  
Table 2. Sinonasal symptoms associated with olfactory or gustatory manifestations 
Sinonasal symptoms 
Olfactory symptoms Gustatory symptoms 
OR (95% CI) p value OR (95% CI) p value 
Nasal obstruction  5·20 (2·24-12·01) 0·000 3·22 (1·48-6·98) 0·003 
Rhinorrhea 1·13 (0·39-3·25) 0·825 1·52 (0·60-3·85) 0·374 
Sneeze 3·33 (1·23-9·01) 0·018 1·57 (0·65-3·78) 0·313 
Headache  2·91(1·46-5·8) 0·002 2·91(0·65-2·70) 0·443 
Facial pain  9·20 (0·98-85·87) 0·051 9·20 (0·47-6·4) 0·408 
CI=confidence interval; OR=odds ratio 
Discussion  
In this study, we investigated the upper airway 
symptoms and their association with smell and 
taste disorders in patients hospitalized with 
COVID-19 in Iran. We report the following 
clinical findings: i) ~one-third of patients 
hospitalised with COVID-19 had olfactory 
symptoms, with both anosmia and hyposmia 
equally distributed in prevalence, ii) the 
olfactory symptoms were sudden onset in ~45% 
of patients, iii) in ~39% of patients with 
olfactory symptoms, change in smell was the 
sole initial manifestation of COVID-19, iv) 
headache and nasal obstruction were 
independently associated with the olfactory 
symptoms, v) hypogeusia was present in ~one-
fourth of patients, often associated with and 
preceded by the olfactory symptoms.  
Compared to prevalence of 85.6% and 88.0% 
for olfactory and gustatory dysfunctions in a 
previous report from mild-to-moderate 
COVID-19 European patients (7), ~one fourth 
and one-third of patients in this study had 
gustatory or olfactory symptoms. We 
questioned directly and specifically about the 
smell and taste problems in our admission 
charts, otherwise there was a high likelihood 
that these symptoms may have gone unnoticed 
in many patients due to the severity of the 
disease. Other likely explanations for the 
discrepancy may be different virulence of 
SARS-CoV-2 in the Iranian versus other 
population. 
Viral infections are the most common cause of 
smell disorders (e.g. anosmia or hyposmia) (8). 
Smell disorders are seen in two forms: 
conductive or sensorineural olfactory loss (9). 
The most common form, conductive olfactory 
loss, is secondary to congestion, secretions and 
inflammatory changes in the nasal mucosa in 
the early days of viral infection with symptoms 
of nasal obstruction and rhinorrhea (9). 
Conversely, in post-viral olfactory disorder, the 
smell disorders including anosmia, hyposmia or 
parosmia occur after the resolution of upper 
airway viral infection, independently of nasal 
obstruction (10,11).  
Coronaviruses are a known cause of post-viral 
olfactory disorder (12). Damage caused by 
coronaviruses may be seen in different 
locations from olfactory epithelium and 
receptor cells to olfactory bulb and central 
processing pathways (8, 9). Commonly, taste 
disorders occur secondary to olfactory 
dysfunction like other viral infections of the 
upper airways (13). In this study, only ~36% of 
patients with olfactory symptoms had nasal 
obstruction, while majority (~75%) of patients 
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with taste disorder also had a smell disorder. 
Taken together, these findings implicate 
sensorineural olfactory loss as the main cause 
of the smell disorder in COVID-19 and suggest 
that gustatory symptoms occur secondary to the 
olfactory dysfunction or due to other unknown 
effects of the virus.  
In ~39% of patients with olfactory symptoms, 
the change in smell was the first symptom of 
COVID-19. Therefore, during the COVID-19 
pandemic, olfactory symptoms like hyposmia, 
anosmia or parosmia may be considered as 
alarm signs for infection with SARS-CoV-2, 
mandating diagnostic testing, early isolation 
and close monitoring of the patients for other 
symptoms of COVID-19. 
Headache was present in ~29% of our study 
population, however it is not a commonly 
reported symptom in most reports of COVID-
19, with its prevalence ranging from 4% to 
13.1% (14-19). Interestingly, in our study, 
headache significantly associated with the 
olfactory symptoms. This association may 
indicate involvement of the central nervous 
system by SARS-CoV-2(19,20). Human 
neuronal cells express the ACE2 receptor, 
which is the cellular binding site for the spike 
protein of SARS-CoV-2 and a potential for 
neurotropism has been documented for almost 
all betacoronaviruses (21). For instance, SARS-
CoV particles were found in the brains of 
patients infected with the virus (20) and 
olfactory neuropathy has been reported during 
SARS outbreak without any improvement after 
2 years (22). Moreover, in experimental 
models, corona-related viruses could involve 
the olfactory bulb with minimal injury of the 
nasal mucosa (23), while intranasal 
introduction of SARS-CoV or MERS-CoV is 
shown to induce brain damage, probably via the 
olfactory nerve(21,24). Lastly, trans-synaptic 
transfer of other coronaviruses has been 
demonstrated (20). Histopathologic 
examination of nasal mucosa, especially 
olfactory cleft area, olfactory bulb, and central 
nervous system on autopsy would shed light on 
the involvement of these organs during the 
course of COVID-19. 
This study has some limitations. The present 
study was performed in a single center. We did 
not perform direct smell and taste identification 
tests and the data were collected by a 
questionnaire. 
Conclusion 
In conclusion, we report a relatively high 
prevalence of olfactory and gustatory 
symptoms in hospitalised patients with 
COVID-19 that were infrequently associated 
with upper respiratory symptoms and not 
uncommonly were the sole initial presenting 
symptoms in the course of the disease. During 
the current pandemic, we strongly suggest that 
specific attention is given to these symptoms in 
assessing the patients with suspected COVID-
19, the presence of which may indicate the need 
for expedited testing for SARS-CoV-2, and 
isolation and close monitoring of the patients 
for evolution of the clinical course. 
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